Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Genmab
Genmab
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Regulatory
Tivdak receives US FDA approval for treating recurrent cervical cancer
The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Drug Delivery
Partnership advances antibody therapies in immunology
Genmab and argenx have entered a multiyear collaboration, bringing together capabilities to jointly discover, develop and commercialise antibody therapies
Regulatory
ImaginAb announces supply agreement with Genmab
The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development
Genmab and Synaffix enter into ADC license agreement
Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies
Manufacturing
Genmab chooses Ibex to take gene candidates to IND in 12 months
New contract extends the partnership between the Danish biotech company and Lonza
Research & Development
Personalised cancer treatment 2.0: new combination strategy developed
Tumours often comprise groups of cancer cells that show differential drug sensitivities, one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients
Ingredients
Tisotumab Vedotin co-developed by Genmab and Seattle Genetics
Genmab and Seattle Genetics announced Seattle Genetics has exercised its option to co-develop tisotumab vedotin
Subscribe now